Par Pharmaceutical (NYSE: PRX ) reported earnings on May 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Par Pharmaceutical beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share dropped.
Gross margins dropped, operating margins dropped, net margins improved.
Par Pharmaceutical tallied revenue of $271.5 million. The nine analysts polled by S&P Capital IQ predicted a top line of $235.7 million on the same basis. GAAP reported sales were 17% higher than the prior-year quarter's $233.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.82. The nine earnings estimates compiled by S&P Capital IQ predicted $0.72 per share. GAAP EPS were -$0.79 for Q1 compared to -$3.07 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 39.3%, 780 basis points worse than the prior-year quarter. Operating margin was 9.5%, 1,280 basis points worse than the prior-year quarter. Net margin was -10.6%, 3,620 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $267.3 million. On the bottom line, the average EPS estimate is $1.03.
Next year's average estimate for revenue is $1.02 billion. The average EPS estimate is $3.74.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Par Pharmaceutical is outperform, with an average price target of $40.89.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Par Pharmaceutical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.
- Add Par Pharmaceutical to My Watchlist.